KLRD1 and neoplasm: We also investigated NK inhibitory receptors: KLRC1 (NKG2A) and KLRD1 (CD94) that suppressed NK cell anti-tumor activity via binding HLA-E30 to evaluate differential NK cell-mediated effects in KIRP and SKCM.